Curaleaf (CURLF) Stock Price, News & Analysis

Company Overview

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. It also provides hemp-based products and cannabinoids, such as cannabidiol and cannabigerol. In addition, the company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. The company is headquartered in New York, New York.

Key Stats

• Today's Range: $1.37 to $1.52
• 50-Day Range: $1.37 to $2.24
• 52-Week Range: $0.88 to $6.40
• Volume: 597,523 shs
• Average Volume: 631,758 shs
• Market Capitalization: $981.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Buy

Curaleaf Stock Analysis - MarketRank™

Curaleaf scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Curaleaf has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Curaleaf has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Curaleaf are expected to grow in the coming year, from ($0.25) to ($0.18) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Curaleaf is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Curaleaf is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Curaleaf has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.04% of the outstanding shares of Curaleaf have been sold short.

Short Interest Ratio / Days to Cover

Curaleaf has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Curaleaf has recently decreased by 6.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Curaleaf does not currently pay a dividend.

Dividend Growth

Curaleaf does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.04% of the outstanding shares of Curaleaf have been sold short.

Short Interest Ratio / Days to Cover

Curaleaf has a short interest ratio ("days to cover") of 4.6.

Change versus previous month

Short interest in Curaleaf has recently decreased by 6.63%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.17

News Sentiment

Curaleaf has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Curaleaf this week, compared to 4 articles on an average week.

Search Interest

8 people have searched for CURLF on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.

MarketBeat Follows

8 people have added Curaleaf to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Curaleaf insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.03% of the stock of Curaleaf is held by institutions.

CURLF Stock Analysis - Frequently Asked Questions

How have CURLF shares performed this year?

Curaleaf's stock was trading at $1.56 on January 1st, 2025. Since then, CURLF shares have decreased by 3.2% and is now trading at $1.51.
View the best growth stocks for 2025 here.

How were Curaleaf's earnings last quarter?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) announced its earnings results on Wednesday, August, 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by $0.01. The firm had revenue of $342.29 million for the quarter, compared to the consensus estimate of $344.57 million. Curaleaf had a negative trailing twelve-month return on equity of 13.67% and a negative net margin of 14.82%.

How do I buy shares of Curaleaf?

Shares of CURLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/07/2024
• Today: 1/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medicinals & botanicals
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CURLF
• CUSIP: N/A
• CIK: 1756770
• Web: www.curaleaf.com
• Phone: 781-451-0351
• Fax: N/A
• Employees: 5,650
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.25
• High Stock Price Target: $6.25
• Low Stock Price Target: $6.25
• Potential Upside/Downside: +313.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-281,200,000.00
• Net Margins: -14.82%
• Pretax Margin: -7.45%
• Return on Equity: -13.67%
• Return on Assets: -4.58%

Debt

• Debt-to-Equity Ratio: 0.85
• Current Ratio: 1.11
• Quick Ratio: 0.51

Sales & Book Value

• Annual Sales: $1.35 billion
• Price / Sales: 0.73
• Cash Flow: $0.15 per share
• Price / Cash Flow: 9.77
• Book Value: $1.64 per share
• Price / Book: 0.92

Miscellaneous

• Outstanding Shares: 649,890,000
• Free Float: N/A
• Market Cap: $981.33 million
• Optionable: Not Optionable
• Beta: 0.64